Local 12: Diabetes study focuses on how long blood sugar control can be maintained
The University of Cincinnati's Robert Cohen, MD, spoke with Local 12 about the GRADE study.
"This was a type two diabetes study, and whereas most studies are looking at how good the blood sugar control can be, this study was focused on how long the blood sugar control can be maintained,” said Cohen, a professor in UC's College of Medicine and UC Health endocrinologist.
Maintaining blood sugar control near normal levels can lower the risk of further complications like heart and kidney disease and vision problems for people with diabetes, Cohen said.
The years-long study found medications now known as Ozempic or Mounjaro were some of the best at maintaining long-term blood sugar control.
“That and insulin itself really did the best job of preserving glycemic blood sugar control,” Cohen said.
As the research continues, Cohen said the team will move beyond drugs that bring down blood sugar levels to evaluate drugs that preserve insulin-producing cells.
Watch or read the Local 12 story.
Featured photo at top of a semaglutide injection pen. Photo/aprott/iStock.
Related Stories
Phenols, found in many products, could upset heart's rhythms
October 7, 2024
Chemicals called environmental phenols include food preservatives, plastics ingredients such as BPA and the parabens in shampoos, so they are ubiquitous in everyday life. Now, University of Cincinnati research suggests that higher exposure to phenols might trigger changes in the heart's electrical system and rhythms.
Local 12, Business Courier highlight Blood Cancer Healing Center
February 19, 2024
Local 12 and the Cincinnati Business Courier highlighted the University of Cincinnati Cancer Center's Blood Cancer Healing Center, a comprehensive all-in-one facility dedicated solely to advancing research, treatment and wellness for blood cancer patients, opening this summer.
Medical News Today: Gene mutation may be a key to lung cancer treatment
September 21, 2022
Medical News Today highlighted recent research led by the University of Cincinnati's Pier Paolo Scaglioni, MD, that found targeting components of lipid metabolism and synthesis could lead to an effective lung cancer treatment.